Genital mycotic infections with canagliflozin 100 and 300mg were evaluated in Population 1 ( N = 2313 ; mean exposure [ weeks ] : canagliflozin , 24.3 ; placebo , 23.8 ) , including patients from four placebo-controlled studies , and Population 2 ( N = 9439 ; mean exposure [ weeks ] : canagliflozin , 68.1 ; control , 64.4 ) , including patients from eight placebo/active-controlled studies ( including older patients and those with renal impairment or high cardiovascular disease risk ) .